Clinical trials: Pulmonary Hypertension, Primary
Pulmonary Arterial Hypertension
Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)
The purpose of the study is to evaluate the safety and tolerability of a rapid dose titration regimen of subcutaneous Remodulin® therapy in patients with PAH.
- Trial name
- RAPID (NCT02847260)
- Testing
- Remodulin
- Volunteers
- 39 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Schistosomiasis
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a severe, progressive and potentially fatal disease that impairs the pulmonary circulation and leads to right ventricular failure.
- Trial name
- SELSCH (NCT04589390)
- Testing
- Selexipag
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- University of Sao Paulo General Hospital
Idiopathic Pulmonary Arterial Hypertension, Primary Pulmonary Hypertension
Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
The purpose of this study is to determine if cardizem is effective in the treatment of nitric oxide non-responder pulmonary arterial hypertension.
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Primary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Familial Primary Pulmonary Hypertension
- Trial name
- NCT01645826
- Testing
- Diltiazem Hydrochloride, Sugar Pill
- Where
- United States
- Sponsor
- University of South Florida
Pulmonary Arterial Hypertension
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that carry blood from the heart to the lungs. PAH occurs when the openings in the blood vessels of the lungs get smaller and smaller.
- Trial name
- ROAR (NCT04813926)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
TReatment Of Pulmonary HYpertension 1 Study
The objective of this study is to assess the safety, performance and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation through subjective and objective change in clinical parameters and…
- Trial name
- TROPHY (NCT02516722)
- Testing
- Therapeutic Intra-Vascular UltraSound (TIVUS™) System
- Where
- 4 sites in Belgium, Israel and 1 more
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Lung Hypoxia, Pulmonary Arterial Hypertension
Iron Status and Hypoxic Pulmonary Vascular Responses
On exposure to hypoxia (low oxygen) the normal response is for pulmonary arterial systolic blood pressure (PASP, blood pressure through the lungs) to increase.
- Conditions
- Lung Hypoxia, Pulmonary Arterial Hypertension, Iron Deficiency
- Trial name
- NCT01847352
- Testing
- Intravenous administration of ferric carboxymaltose, Subacute hypoxic exposures
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Pulmonary Arterial Hypertension
Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)
Administration of iloprost aerosol comparing two nebulizers: FOX and I-Neb
- Trial name
- NCT02032836
- Testing
- lloprost(Ventavis,BAYQ6252, 20 µg/mL), lloprost(Ventavis,BAYQ6252, 10 µg/mL)
- Where
- 6 sites in Austria, Germany
- Volunteers
- 27 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart.
- Trial name
- SOTERIA (NCT07218029)
- Testing
- Sotatercept
- Where
- 137 sites in United States, Argentina and 25 more
- Volunteers
- 815 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to see if Lung LLC's new experimental formulation of the medicine Beraprost Sodium, called Beraprost Sodium 314d Modified Release (BPS-314d-MR), can improve the symptoms of pulmonary arterial…
- Trial name
- NCT01966302
- Testing
- BPS-314d-MR
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Pulmonary Arterial Hypertension
Prevalence of Musculoskeletal Pain and Its Impact on Quality of Life and Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension
Prevalence of musculoskeletal pain and its impact of quality of life and functional exercise capacity will be evaluated in patients with pulmonary arterial hypertension.
- Trial name
- NCT04808830
- Testing
- Evaluation of musculoskeletal pain prevalence, Evaluation of quality of life, Evaluation of functional exercise capacity
- Where
- Turkey (Türkiye)
- Volunteers
- 61 people
- Sponsor
- Izmir Bakircay University
Pulmonary Arterial Hypertension
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers
In this prospective study, the investigators will implement a systematic screening program and 3-year follow-up in a cohort of asymptomatic BMPR2 mutation carriers.
- Trial name
- DELPHI-2 (NCT01600898)
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Hypertension, Sickle Cell Disease
Macitentan in Pulmonary Hypertension of Sickle Cell Disease
This is a pilot study to assess the safety and efficacy of macitentan in patients with pulmonary hypertension of sickle cell disease. This study will enroll approximately 10 subjects.
- Trial name
- MENSCH (NCT02651272)
- Testing
- macitentan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Boston University
Hypertension, Pulmonary
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
The main aim of the observational VENTASTEP study was to investigate the association between changes in clinical outcome measures and changes in device outcome measures in PAH patients using the new Breelib nebulizer in a real…
- Trial name
- VENTASTEP (NCT03293407)
- Testing
- Iloprost (Ventavis, BAYQ6256), Breelib nebulizer
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
ACT-293987 in Pulmonary Arterial Hypertension
Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
- Trial name
- NCT01112306
- Testing
- ACT-293987
- Where
- 157 sites in United States, Argentina and 36 more
- Volunteers
- 709 people
- Sponsor
- Actelion
Hypertension, Pulmonary
Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular affection, which treatment has evolved in the last few years, improving quality of life. However, adherence to treatment has not been assessed in such patients.
- Trial name
- ETHAP (NCT01038284)
- Testing
- Patient education, Data collection
- Where
- 11 sites in France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Grenoble
Pulmonary Idiopathic Arterial Hypertension
Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension
Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair. Current evidence established that endothelial progenitor cells (EPC) participate in several models of…
- Trial name
- NCT00551408
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Unidad de Investigacion Clinica en Medicina S.C.
Hypertension, Pulmonary
A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
The purpose of this study is to determine whether aspirin and simvastatin are safe and effective for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT00384865
- Testing
- Simvastatin, Aspirin
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of Pennsylvania
Pulmonary Hypertension, Pulmonary Arterial Hypertension
The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension
The aim of this study is to 1) descriptively report possible in flight events and 2) to provide regression analysis if the number of events are statistically significant in their prevalence and thus are useful in finding possible…
- Trial name
- PEGASUS (NCT03051763)
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 1,000 people
- Sponsor
- University of Giessen
Schistosomiasis
Assessment of Right Ventricular-Pulmonary Arterial Coupling in Schistosomiasis-Associated Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension is a progressive and potentially fatal cardiopulmonary disorder characterized by remodeling of the pulmonary vasculature, progressive elevation of pulmonary vascular resistance (PVR), and eventual…
- Trial name
- Sch-PAH RV-PA (NCT07707193)
- Testing
- right heart catheterization for measure pulmonary artery pressure
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are severe clinical conditions that, despite advances in therapeutics over the past 20 years, lead to serious morbidity and…
- Trial name
- NCT05618093
- Testing
- Non-invasive hemodynamic measurements
- Where
- United States
- Sponsor
- University of California, Los Angeles